Globulin ag ratio
Pro Research Analysisby 
Searched over 200M research papers
Prognostic Value of Albumin-to-Globulin Ratio (AGR) in Cancer and Other Diseases
Introduction to Albumin-to-Globulin Ratio (AGR)
The albumin-to-globulin ratio (AGR) is a significant biomarker derived from serum protein levels, specifically albumin and globulin. This ratio has been extensively studied for its prognostic value in various diseases, particularly cancers. AGR reflects the nutritional and immune status of patients, making it a valuable indicator in clinical settings.
AGR as a Prognostic Marker in Cancer
General Cancer Prognosis
Multiple studies have demonstrated that a low pretreatment AGR is associated with poor overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in cancer patients. A meta-analysis involving 15,356 cancer patients revealed that low AGR is linked to poor OS (HR=2.08), DFS (HR=1.96), and PFS (HR=1.89), as well as increased 5-year mortality (RR=2.12) . Another comprehensive review of 13,890 solid tumor patients confirmed that higher AGR correlates with better OS, cancer-specific survival (CSS), DFS, and disease-metastasis-free survival (DMFS) .
Specific Cancer Types
Prostate Cancer
In prostate cancer (PC), AGR has shown varying prognostic values depending on the stage of the disease. For non-metastatic PC, AGR did not significantly predict staging, grading, or biochemical progression. However, in metastatic PC, a low AGR was significantly associated with worse PFS and CSS .
Digestive System Cancers
A meta-analysis of digestive system cancers (DSCs) involving 9,269 patients found that a low AGR was significantly correlated with poor OS (HR=1.94) and DFS (HR=1.49) . Similarly, in colorectal cancer (CRC), low AGR was linked to poor OS (HR=2.58) and DFS/PFS (HR=2.11) .
Gastric Cancer
In gastric cancer (GC), low AGR was associated with worse OS (HR=1.531) and DFS/PFS (HR=2.008) . This association remained consistent across different countries, tumor stages, and treatment methods.
Lymphoma
For patients with diffuse large B-cell lymphoma (DLBCL), a low AGR was significantly associated with poorer OS. Multivariate analysis confirmed that low AGR is an independent adverse predictor for OS .
Head and Neck Cancer
In head and neck cancer (HNC), low AGR was significantly associated with poor DFS, distant metastasis-free survival, OS, advanced T3-T4 status, stage III-IV disease, and lymph node metastasis .
Lymph Node Metastasis
AGR has also been linked to lymph node metastasis (LNM) in various cancers. A systematic review and meta-analysis involving 4,136 patients found that low AGR significantly increased the risk of LNM (HR=2.24) .
AGR in Non-Cancer Diseases
Microscopic Polyangiitis
AGR has prognostic value beyond cancer. In microscopic polyangiitis (MPA), a low AGR at diagnosis was inversely associated with all-cause mortality during follow-up. Patients with an AGR ≤ 0.88 had a significantly lower cumulative survival rate .
Conclusion
The albumin-to-globulin ratio (AGR) is a valuable prognostic marker across various cancers and other diseases. Low pretreatment AGR is consistently associated with poor survival outcomes, increased risk of disease progression, and higher mortality rates. Given its cost-effectiveness and reliability, AGR should be considered in clinical practice for prognostic assessment and treatment planning. Further large-scale prospective studies are needed to validate these findings and explore the full potential of AGR in different clinical settings.
Sources and full results
Most relevant research papers on this topic